Reported Nov 21, 2018 · Terminated
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone…
Eli Lilly & Co.
Low riskThis product is unlikely to cause harm, but it breaks a safety or labelling rule.What you should do
Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.
Firm contact: Eli Lilly & Co · 1 Lilly Corporate Ctr · Indianapolis, IN · 46285-0001
Is this the product you have?
- ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only
- Manufactured byImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA
- NDC66733-958-23
- Lot codes and dates
- Lot number
C1700167exp 9/2020
- Lot number
- Amount recalled
- 9,380 vials
Where it was sold
Why it was recalled
Labeling: Missing label; potential for missing primary container label on the vial.
This product is unlikely to cause harm, but it breaks a safety or labelling rule.
Want the full recall guide?
The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.
Free recall alerts
Get alerted about new Eli Lilly & Co. recalls
One email when a matching recall is published. No account, no cost, unsubscribe in one click.
We email you about recalls and nothing else. Every send has a one-click unsubscribe, and you can change your preferences any time without an account.